As the pace of treatment innovation threatens the financial health of both patients and oncology practices,...
Other content in this Stream
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
The therapeutic landscape in oncology is vast and everchanging, marked by a dramatic pace of innovation and new approvals. In this complicated specialty, how can payers and providers keep up?
In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.
Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.
A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.
NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.
Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.
Recent journal article details how NCH and Cancer Care Specialists of Illinois teamed up to slow growth in drug spend.
Increasing use of real-world evidence is one of the most exciting trends in pathway development, our CMO tells Journal of Clinical Pathways.
Medscape delves into our work with a community oncology practice to implement high-value clinical pathways and engage providers
Our chief medical officer, Dr. Andrew Hertler, speaks with Journal of Clinical Pathways about our approach to high-value cancer care.
Cancer Care Specialists of Illinois reduced drug spend by 13.5% compared to peer practices by deploying our care pathway and physician collaboration protocols
Navigating the CMS Oncology Care Model can be complicated. Listen to oncologist Dr. Wade describe his OCM experiences and how a partnership with New Century Health positioned his practice for success.